Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T06:54:43.796Z Has data issue: false hasContentIssue false

Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent

Published online by Cambridge University Press:  09 February 2024

Jeffrey R. Strawn  and
Stephen M. Stahl
Jeffrey R. Strawn
Affiliation:
University of Cincinnati, Ohio
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Which of the following represents the best and most evidence-based intervention for an adolescent with MDD who failed to respond to escitalopram (Lexapro) 20 mg daily for 4 months, and in whom escitalopram was discontinued 2 months ago?

Type
Chapter
Information
Case Studies: Stahl's Essential Psychopharmacology
Children and Adolescents
 , pp. 49 - 64
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Asarnow, J. R., Emslie, G., Clarke, G., et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48: 330–39. https://doi.org/10.1097/chi.0b013e3181977476Google Scholar
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 2023; 114: 51–68. https://doi.org/10.1002/cpt.2903Google Scholar
Compton, S. N., Peris, T. S., Almirall, D., et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol 2014; 82: 212–24. https://doi.org/10.1037/a0035458Google Scholar
Dobson, E. T., Bloch, M. H., Strawn, J. R. Efficacy and tolerability of pharmacotherapy in pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry 2019; 80: 17r12064. https://doi.org/10.4088/JCP.17r12064Google Scholar
Emslie, G. J., Prakash, A., Zhang, Q., et al. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24: 170–79. https://doi.org/10.1089/cap.2013.0096Google Scholar
Greenblatt, D. J., Divoll Allen, M., Harmatz, J. S., Shader, R. I. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 301–12. https://doi.org/10.1038/clpt.1980.40Google Scholar
Gunlicks-Stoessel, M., Mufson, L., Bernstein, G., et al. Critical decision points for augmenting interpersonal psychotherapy for depressed adolescents: a pilot sequential multiple assignment randomized trial. J Am Acad Child Adolesc Psychiatry 2019; 58: 80–91. https://doi.org/10.1016/j.jaac.2018.06.032Google Scholar
Kneller, L. A., Zubiaur, P., Koller, D., Abad-Santos, F., Hempel, G. Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clin Pharmacokinet 2021; 60: 1569–82. https://doi.org/10.1007/s40262-021-01041-xGoogle Scholar
Locher, C., Koechlin, H., Zion, S. R., et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and placebo in common psychiatric disorders: a meta-analysis in children and adolescents. JAMA Psychiatry 2017; 74: 1011–20. https://doi.org/10.1001/jamapsychiatry.2017.2432Google Scholar
Shah, R. R., Smith, R. L. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol 2015; 79: 222–40. https://doi.org/10.1111/bcp.12441CrossRefGoogle ScholarPubMed
Shamseddeen, W., Clarke, G., Keller, M. B., et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol 2012; 22: 29–36. https://doi.org/10.1089/cap.2011.0027Google Scholar
Strawn, J. R., Prakash, A., Zhang, Q., et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 2015; 54: 283–93. https://doi.org/10.1016/j.jaac.2015.01.008Google Scholar
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., Levine, A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018a; 19: 1057–70. https://doi.org/10.1080/14656566.2018.1491966Google Scholar
Strawn, J. R., Mills, J. A., Sauley, B. A., Welge, J. A. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2018b; 57: 235–44.e2. https://doi.org/10.1016/j.jaac.2018.01.015Google Scholar
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., Walkup, J. T. Research review: pediatric anxiety disorders – what have we learnt in the last 10 years? J Child Psychol Psychiatry 2021; 62: 114–39. https://doi.org/10.1111/jcpp.13262Google Scholar
Suresh, V., Mills, J. A., Croarkin, P. E., Strawn, J. R. What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression. Depress Anxiety 2020; 37: 926–34. https://doi.org/10.1002/da.23064Google Scholar
Walkup, J. T., Albano, A. M., Piacentini, J., et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753–66. https://doi.org/10.1056/NEJMoa0804633Google Scholar
Williams, T., Hattingh, C. J., Kariuki, C. M., et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev 2017; 10: CD001206. https://doi.org/10.1002/14651858.CD001206.pub3Google Scholar
Zanger, U. M., Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×